Health Care

Gary Godsey, President and CEO of the PKD Foundation, explains what resources the Foundation provides for patients and how they're working with researchers to repurpose compounds through the "Accelerating Treatment to Patients” initiative. He encourages listeners to take the 31 Day PKD Challenge as part of National Kidney Month and to join him on Facebook.

Lisa Tate, CEO of WomenHeart, the National Coalition for Women with Heart Disease, discusses what we can each do to prevent heart disease.

Drugs approved with companion diagnostic tests represent the next wave of personalized medicine and have the potential to significantly improve patient outcomes.

BIO Asia will be held January 31 – February 1, 2012 in Osaka, Japan.

Learn about the role biotechnology plays in the on-going fight against HIV/AIDS.

Diseases of the eye affect more than 10 million Americans, and biotechnology holds great promise for treatments and cures

In three minutes, this video tells the pertinent story of how recombinant DNA technology was used to produce human — or synthetic — insulin in large amounts and how it became the first biotechnology treatment approved by the FDA.

BIOtech-NOW talks to Laurence Marton, Co-Chair of the Personalized Medicine World Conference 2012, about the outlook for personalized medicine.

The world's best hope for turning breast cancer — and other forms of cancer — into a chronic manageable disease lies within biotechnology.

BIO President and CEO Jim Greenwood congratulated the FDA and biopharmaceutical sponsors for making 35 novel new treatments available to patients in FY11.

Underlying the PDUFA V recommendations are the principles that a science-based, transparent, and well-managed review process that appropriately balances benefits and risks can enhance public trust and increase patient access to new medicines.

Kuldip Dave from the Michael J. Fox Foundation discusses his organization's work to reposition drugs for Parkinson's Disease.

Since the development of the first vaccine by Edward Jenner in 1796, we have seen tremendous progress in our ability to prevent deadly childhood infections.

Regulatory review processes are not keeping up with rapidly advancing science and are making the environment for developing new treatments and preventions for deadly and debilitating diseases more difficult.

Letters, Testimony & Comments

May 8 2013
  Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for...
May 7 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
April 19 2013
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the “WHO Guidelines on the Quality...
April 12 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
April 8 2013
BIO supports the goals of the Affordable Care Act (ACA) in providing greater transparency regarding financial relationships with...

Press Releases

May 24 2013
Washington, D.C. – Rx Response elevated its status to Alert and has activated Rx Open in the aftermath of the...
February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
January 25 2013
The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All...
October 1 2012
Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and...
July 23 2012
Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping...